Session Title: Vascular Diseases I
Session Date/Time: Friday 27/09/2013 | 08:00-10:00
Paper Time: 08:40
Venue: Hall C (Level 1)
First Author: A.Abu El Asrar SAUDI ARABIA
Endocan, a proteoglycan specifically secreted by endothelial cells, is a marker of angiogenesis and endothelial cell activation in response to proangiogenic signals. The aim of this study was to measure the levels of endocan in the vitreous fluid from patients with proliferative diabetic retinopathy (PDR) and to correlate its levels with clinical disease activity and the levels of the angiogenic biomarkers vascular endothelial growth factor (VEGF), soluble vascular endothelial-cadherin (sVE-cadherin) and soluble endoglin (sEng).
Vitreous samples from 44 PDR and 29 nondiabetic patients were studied by enzyme-linked immunosorbent assay.
Endocan, VEGF, sVE-cadherin and sEng levels were significantly higher in PDR patients than in nondiabetic patients (p<0.001; p=0.002; p<0.001; p=0.001, respectively). Endocan levels were significantly higher in patients with active PDR than in patients with inactive PDR and nondiabetic patients (p<0.001). There were significant correlations between endocan levels and the levels of VEGF (r=0.574, p<0.001) and the levels of sVE-cadherin (r=0.498, p<0.001).
Endocan could be a new biomarker of endothelial cell activation and angiogenesis in PDR and may be a useful therapeutic target.